LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE - Generic Drug Details

✉ Email this page to a colleague

What are the generic sources for lamivudine; nevirapine; zidovudine and what is the scope of patent protection?

Lamivudine; nevirapine; zidovudine is the generic ingredient in one branded drug marketed by Micro Labs and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are seven tentative approvals for this compound.

Summary for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	45
DailyMed Link:	LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE at DailyMed

Recent Clinical Trials for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Aurum Institute NPC	Phase 1/Phase 2
Johns Hopkins University	Phase 1/Phase 2
ANRS, Emerging Infectious Diseases	Phase 4

See all LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE clinical trials

Generic filers with tentative approvals for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Applicant	Application No.	Strength	Dosage Form
⤷ Sign Up	⤷ Sign Up	150MG; 200MG; 300MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	150MG; 200MG; 300MG	TABLET; ORAL
⤷ Sign Up	⤷ Sign Up	30MG; 50MG; 60MG	TABLET, FOR SUSPENSION; ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Anatomical Therapeutic Chemical (ATC) Classes for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

US Patents and Regulatory Information for LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Micro Labs	LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE	lamivudine; nevirapine; zidovudine	TABLET;ORAL	205626-001	Aug 13, 2018		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.